DE60029029D1 - Selektion von FXR-Rezeptormodulatoren - Google Patents

Selektion von FXR-Rezeptormodulatoren

Info

Publication number
DE60029029D1
DE60029029D1 DE60029029T DE60029029T DE60029029D1 DE 60029029 D1 DE60029029 D1 DE 60029029D1 DE 60029029 T DE60029029 T DE 60029029T DE 60029029 T DE60029029 T DE 60029029T DE 60029029 D1 DE60029029 D1 DE 60029029D1
Authority
DE
Germany
Prior art keywords
fxr
selection
receptor modulators
methods
fxr receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60029029T
Other languages
English (en)
Other versions
DE60029029T2 (de
Inventor
Barry M Forman
Haibo Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Application granted granted Critical
Publication of DE60029029D1 publication Critical patent/DE60029029D1/de
Publication of DE60029029T2 publication Critical patent/DE60029029T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
DE60029029T 1999-03-26 2000-03-24 Screenen nach FXR-Rezeptormodulatoren Expired - Fee Related DE60029029T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12633499P 1999-03-26 1999-03-26
US126334P 1999-03-26

Publications (2)

Publication Number Publication Date
DE60029029D1 true DE60029029D1 (de) 2006-08-03
DE60029029T2 DE60029029T2 (de) 2007-06-14

Family

ID=22424256

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60013417T Expired - Fee Related DE60013417T2 (de) 1999-03-26 2000-03-24 Verfahren zum screenen von fxr-rezeptormodulatoren
DE60029029T Expired - Fee Related DE60029029T2 (de) 1999-03-26 2000-03-24 Screenen nach FXR-Rezeptormodulatoren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60013417T Expired - Fee Related DE60013417T2 (de) 1999-03-26 2000-03-24 Verfahren zum screenen von fxr-rezeptormodulatoren

Country Status (7)

Country Link
EP (1) EP1165135B1 (de)
JP (1) JP2004510682A (de)
AT (2) ATE330632T1 (de)
AU (1) AU780658B2 (de)
CA (1) CA2368234A1 (de)
DE (2) DE60013417T2 (de)
WO (1) WO2000057915A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002532729A (ja) 1998-12-23 2002-10-02 グラクソ グループ リミテッド 核内受容体のリガンドのアッセイ
WO2002022817A2 (en) * 2000-09-16 2002-03-21 Lion Bioscience Ag Nuclear receptor l66 and methods of use
FR2820435B1 (fr) * 2001-02-05 2004-02-27 Genfit S A Procedes d'identification de composes modulant le transport inverse du cholesterol
USRE48286E1 (en) 2001-03-12 2020-10-27 Intercept Pharmaceuticals, Inc. Steroids as agonists for FXR
US7053076B2 (en) 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
EP1465882B1 (de) 2001-12-21 2011-08-24 X-Ceptor Therapeutics, Inc. Heterocyclische modulatoren von nukleären rezeptoren
CA2469435A1 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
US6987121B2 (en) 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
DE60335911D1 (de) 2002-12-20 2011-03-10 Daiichi Sankyo Co Ltd Isochinolinonderivate und deren verwendung als medikamente
DK1734970T3 (en) 2004-03-12 2015-02-16 Intercept Pharmaceuticals Inc Treatment of fibrosis using FXR ligands
US10987362B2 (en) 2004-03-12 2021-04-27 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
US7781175B2 (en) * 2004-04-23 2010-08-24 Takeda Pharmaceutical Company Limited Method of screening compounds which alter the binding properties of GPR39, and homologs thereof, to bile acid
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
BRPI0612287A8 (pt) 2005-06-27 2019-01-22 Exelixis Inc composição para uso farmacêutico no tratamento de doenças através da medicina nuclear e métodos de uso e para modulação de atividade de receptor nuclear
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
CN101679476B (zh) 2007-01-19 2014-05-07 英特塞普特医药品公司 23取代的胆汁酸作为tgr5调节剂及其使用方法
BRPI0916735B8 (pt) 2008-07-30 2021-05-25 Intercept Pharmaceuticals Inc compostos moduladores de tgr5, composições farmacêuticas compreendendo os mesmos e seus usos
MX2011005295A (es) 2008-11-19 2011-06-24 Intercept Pharmaceuticals Inc Moduladores de tgr5 y metodo de uso de los mismos.
SI2435410T1 (sl) 2009-05-28 2017-06-30 Bristol-Myers Squibb Company Lxr modulatorji
TW201242953A (en) 2011-03-25 2012-11-01 Bristol Myers Squibb Co Imidazole prodrug LXR modulators
ES2659455T3 (es) * 2011-09-19 2018-03-15 ETH Zürich Moduladores del ROR gamma para tratar complicaciones de diabetes II
EP2861259A1 (de) 2012-06-14 2015-04-22 Ambrx, Inc. An kernrezeptor-ligandenpolypeptide konjugierte anti-psma-antikörper
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
CA3047776C (en) 2012-06-19 2022-10-18 Intercept Pharmaceuticals, Inc. Preparation, uses and solid forms of obeticholic acid
EP2781217A1 (de) * 2013-03-18 2014-09-24 ETH Zurich ROR-Gammamodulatoren
US11208664B2 (en) 2016-09-12 2021-12-28 Massachusetts Institute Of Technology Transcriptional sensor for bile acids in bacteroides thetaiotaomicron

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294376B1 (en) * 1993-02-05 2001-09-25 Merrill Overturf Cholesterol 7-alpha hydroxylase expression regulation
CA2231547A1 (en) * 1995-10-11 1997-04-17 Kevin Jon Williams Liposomal compositions and methods of using them
AU2332497A (en) * 1996-03-19 1997-10-10 Salk Institute For Biological Studies, The (in vitro) methods for identifying modulators of members of the steroid/thyroid superfamily of receptors
WO1997035196A1 (en) * 1996-03-20 1997-09-25 Dyax Corp. Engineering affinity ligands for macromolecules

Also Published As

Publication number Publication date
ATE330632T1 (de) 2006-07-15
AU780658B2 (en) 2005-04-07
WO2000057915A1 (en) 2000-10-05
AU3917300A (en) 2000-10-16
JP2004510682A (ja) 2004-04-08
DE60029029T2 (de) 2007-06-14
DE60013417D1 (de) 2004-10-07
CA2368234A1 (en) 2000-10-05
ATE274921T1 (de) 2004-09-15
DE60013417T2 (de) 2005-09-15
EP1165135B1 (de) 2004-09-01
EP1165135A1 (de) 2002-01-02

Similar Documents

Publication Publication Date Title
ATE330632T1 (de) Selektion von fxr-rezeptormodulatoren
WO2003030612A3 (en) Methods for modulating activity of the fxr nuclear receptor
EP1073465A4 (de) T-zell inhibierende rezeptorzusammensetzungen sowie deren verwendung
ATE245993T1 (de) Allosterische modulatoren des nmda-rezeptors
NO20050717L (no) Metode og sammensetninger for modulering av T hjelpe (TH) celleutvikling og funksjon
BR9710988A (pt) Método e compostos moduladores receptores de androgênio
WO2005117968A3 (en) Compositions and methods comprising an egfl7 antagonist for modulating vascular development
WO2003068944A3 (en) METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1α-
AU2003228283A1 (en) Quinazolinone modulators of nuclear receptors
NO20070898L (no) Diversitetsinnfelling av kodebiter ved plassering og blanding
NO960767L (no) Protocadherinproteiner og deres anvendelse
MX339420B (es) Compuestos para la modulacion de la actividad de ppar gamma.
DE69835225D1 (de) Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen
NO980198L (no) Modulatorer av funksjonen til FAS-reseptorer og andre proteiner
ATE342969T1 (de) Ribozyme die fähig sind die expression des ccr5 rezeptor zu hemmen
AU4981500A (en) Cancer treatment with endothelin receptor antagonists
DK1200831T3 (da) Modulatorisk bindingssted i kaliumkanaler til screening
IL124652A (en) Screening assay for compounds stimulating somatostatin and insulin production
WO2002044376A3 (en) Modulation of gene expression using insulator binding proteins
DE60033576D1 (de) Methoden zum screening knochenmorphogenetishemimetika
MXPA05011157A (es) Nuevo metodo para modular la actividad relacionada a los huesos.
ATE321887T1 (de) Verfahren zur identifizierung von modulatoren des cholesterinrückwärtstransportes
DE60102539D1 (de) Verfahren und Zusammensetzungen zum Screenen von Modulatoren von Sphingosinkinasen
DK1007649T3 (da) Fremgangsmåder til screening for interaktioner mellem transkriptionsfaktor og coaktivator
WO1998054344A3 (en) Modulators of morphogen expression and methods of identifying the same

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee